Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

Zacks
在Zacks上打开
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $517.49, demonstrating a -1.23% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.7% for the day. On the other hand, the Dow registered a gain of 0.28%, and the technology-centric Nasdaq increased by 0.83%.

The drugmaker's stock has dropped by 0.43% in the past month, falling short of the Medical sector's gain of 3.23% and outpacing the S&P 500's loss of 1.21%.

The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. The company's earnings report is expected on November 2, 2026. The company is predicted to post an EPS of $4.92, indicating a 2.5% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $3.4 billion, indicating a 10.62% growth compared to the corresponding quarter of the prior year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.92 per share and a revenue of $13.22 billion, signifying shifts of +2.83% and +10.16%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for Vertex Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.63% upward. Right now, Vertex Pharmaceuticals possesses a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Vertex Pharmaceuticals has a Forward P/E ratio of 27.69 right now. Its industry sports an average Forward P/E of 25.2, so one might conclude that Vertex Pharmaceuticals is trading at a premium comparatively.

It's also important to note that VRTX currently trades at a PEG ratio of 2.22. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.77 at the close of the market yesterday.

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 100, positioning it in the top 41% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow VRTX in the coming trading sessions, be sure to utilize Zacks.com.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research